Pfizer filed, on Friday (30), with a request for emergency use of a new version of its bivalent vaccine against Covid. The updated type of immunizer relies on the original Sars-CoV-2 strain and the BA.4/BA.5 subvariants.
The indication would be for use as a booster dose in people over 12 years of age.
In August, the drugmaker had already applied for authorization for emergency use of a bivalent version of the vaccine adapted to the Omicron variant BA.1, which quickly spread throughout the world. That request is still under review.
When documented — by a Brazilian scientist, including —, the ômicron variant caught the attention of the scientific community for the high amount of changes in the spike protein, which is used by Sars-CoV-2 to bind to our cells and invade them. .
An important point is that this protein is central to the action of vaccines. Therefore, there were fears that changes in Spike’s genetic information could eventually lead to a vaccine leak.
In fact, with the variants, there was a greater escape from the immunization promoted by the immunizers, but, even so, the different doses of vaccines proved capable, to a large extent, of stopping the virus.
I have over 3 years of experience working in the news industry. I have worked for various news websites and have been an author at News Bulletin 247 for the past 2 years. I mostly cover technology news and have a keen interest in keeping up with the latest trends in the industry. I am a highly motivated individual who is always looking to improve my skills and knowledge.
